nach oben

Sleep and Breathing

Erschienen in:

10.07.2019 | Neurology • Review

Narcolepsy treatment: pharmacological and behavioral strategies in adults and children

verfasst von: Christian Franceschini, Fabio Pizza, Elena Antelmi, Maria Claudia Folli, Giuseppe Plazzi

Erschienen in: Sleep and Breathing | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Narcolepsy is a disabling, rare, and chronic sleep disorder, currently classified as distinct central nervous system hypersomnia in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Although today a reliable pathogenic hypothesis identifies the cause of NT1 as an autoimmune process destroying hypocretin-producing cells, there is no cure for narcolepsy, and the symptomatic pharmacological available treatments are not entirely effective for all symptoms. Behavioral therapies play a synergistic role in the disease treatment. We here review the available therapeutic options for narcolepsy, including symptomatic pharmacological treatments as well as behavioral and psychosocial interventions that could help clinicians improve the quality of life of patients with narcolepsy in adulthood and childhood.

AASM: American Academy of Sleep Medicine (2014) ICSD-3: international classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, Daniel

Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DNC, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. PNAS 96:10911–10916. https://doi.org/10.1073/pnas.96.19.10911 CrossRef

Sutcliffe JG, de Lecea L (2000) The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 62:161–168. https://doi.org/10.1002/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1 CrossRef

Brown RE, Sergeeva O, Eriksson KS, Haas H (2001) Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 40:457–459. https://doi.org/10.1016/S0028-3908(00)00178-7 CrossRef

Dye TJ, Gurbani N, Simakajornboon N (2018) Epidemiology and pathophysiology of childhood narcolepsy. Paediatr Respir Rev 25:14–18. https://doi.org/10.1016/j.prrv.2016.12.005 CrossRef

Shibata M, Mondal MS, Date Y, Nakazato M, Suzuki H, Ueta Y (2008) Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb. Neuroscience research, 61-99-105. https://doi.org/10.1016/j.neures.2008.01.017

Tashiro T, Kanbayashi T, Iijima S, Hishikawa Y (1992) An epidemiological study of narcolepsy in Japanese. J Sleep Res 1:228

Mignot E (1998) Genetic and familial aspects of narcolepsy. Neurology 50:S16–S22. https://doi.org/10.1212/WNL.50.2_Suppl_1.S16 CrossRef

Baumann CR, Mignot E, Lammers GJ, Overeem S, Arnulf I, Rye D, Dauvilliers Y, Honda M, Owens JA, Plazzi G, Scammell TE (2014) Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 37:1035–1042. https://doi.org/10.5665/sleep.3756 CrossRef

10.

Miyagawa T, Tokunaga K (2019) Genetics of narcolepsy. Hum Genome Var 6:4. https://doi.org/10.1038/s41439-018-0033-7 CrossRef

11.

Postiglione E, Antelmi E, Pizza F, Lecendreux M, Dauvilliers Y, Plazzi G (2018) The clinical spectrum of childhood narcolepsy. Sleep Med Rev 38:70–85. https://doi.org/10.1016/j.smrv.2017.04.003 CrossRef

12.

Dauvilliers Y, Jaussent I, Krams B, Scholz S, Lado S, Levy P, Pepin JL (2012) Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One 7:e38977. https://doi.org/10.1371/journal.pone.0038977 CrossRef

13.

Fortuyn HA, Mulders PC, Renier WO, Buitelaar JK, Overeem S (2011) Narcolepsy and psychiatry: an evolving association of increasing interest. Sleep Med 12:714–719. https://doi.org/10.1016/j.sleep.2011.01.013 CrossRef

14.

Rocca FL, Pizza F, Ricc E, Plazzi G (2015) Narcolepsy during childhood: an update. Neuropediatrics 46:181–198. https://doi.org/10.1055/s-0035-1550152 CrossRef

15.

Ingravallo F, Gnucci V, Pizza F, Vignatelli L, Govi A, Dormi A, Pelotti S, Cicognani A, Dauvilliers Y, Plazzi G (2012) The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med 13:1293–1300. https://doi.org/10.1016/j.sleep.2012.08.002 CrossRef

16.

Ton TG, Watson NF, Koepsell TD, Longstreth WT (2014) Narcolepsy and the sickness impact profile: a general health status measure. Sleep Sci 7:5–12. https://doi.org/10.1016/j.slsci.2014.07.001 CrossRef

17.

Scammell TE, Estabrooke IV, McCarthy MT et al (2000) Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20:8620–8628. https://doi.org/10.1523/JNEUROSCI.20-22-08620.2000 CrossRef

18.

Wisor J (2013) Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol 4:139. https://doi.org/10.3389/fneur.2013.00139 CrossRef

19.

Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, Pollmächer T, Reading P, Sonka K; EFNS Task Force (2006) EFNS Task Force. EFNS guidelines on management of narcolepsy. Eur J Neurol 13:1035–1048. https://doi.org/10.1111/j.1468-1331.2006.01473.x

20.

Morgenthaler TI, Kapur VK, Brown T et al (2007) Standards of practice committee of the AASM. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30:1705–1711. https://doi.org/10.1093/sleep/30.12.1750 CrossRef

21.

Schwartz JR, Feldman NT, Bogan RK (2005) Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry ClinNeurosci 17:405–412. https://doi.org/10.1176/jnp.17.3.405 CrossRef

22.

Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ (2003) Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 26:252–257CrossRef

23.

Schwartz JR, Nelson MT, Schwartz ER, Hughes RJ (2004) Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 27:74–79CrossRef

24.

Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, Lubin S (1994) Modafinil: a double-blind multicentric study. Sleep 17:S107–S112CrossRef

25.

Broughton RJ, Fleming JA, George CF et al (1997) Randomized, doubleblind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49:444–451CrossRef

26.

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group (2000). Neurology 54:1166–1175. https://doi.org/10.1212/WNL.54.5.1166

27.

Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, Wang L, Goswami M, Steinwald B (1999) Health- related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22:757–765CrossRef

28.

Palovaara S, Kivistö KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K (2000) Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam l-hydroxylation. Br J Clin Pharm 50:333–337. https://doi.org/10.1046/j.1365-2125.2000.00271.x CrossRef

29.

Kallweit U, Bassetti CL (2017) Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother 18:809–817. https://doi.org/10.1007/s11940-015-0347-4 CrossRef

30.

Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, Niebler GE, Roth T (2006) The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 22:761–774. https://doi.org/10.1185/030079906X100050 CrossRef

31.

Lin J-S, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients. Neurobiol Dis 30:74–83. https://doi.org/10.1016/j.nbd.2007.12.003 CrossRef

32.

Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomized trial. Lancet Neurol 12:1068–1075. https://doi.org/10.1016/S1474-4422(13)70225-4 CrossRef

33.

Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC, Poluektov M, Yakupov E, Kalinkin A, Aksu M, Yilmaz H, Benbir G, Wolynczyk-Gmaj D, Jernajczyk W, Staykov I, Tavarari AN (2017) Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200–207. https://doi.org/10.1016/S1474-4422(16)30333-7 CrossRef

34.

Syed YY (2016) Pitolisant: first global approval. Drugs 76:1313–1318. https://doi.org/10.1007/s40265-016-0620-1 CrossRef

35.

Mamelak M, Escriu JM, Stokan O (1977) The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry 12:273–288

36.

Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J (2017) Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res 26:407–414. https://doi.org/10.1111/jsr.12468 CrossRef

37.

Houghton WC, Scammell TE, Thorpy M (2004) Pharmacotherapy for cataplexy. Sleep Med Rev 8:355–366. https://doi.org/10.1016/j.smrv.2004.01.004 CrossRef

38.

Mansukhani M, Kotagal S (2012) Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study. Sleep Med 13:606–610. https://doi.org/10.1016/j.sleep.2011.10.032 CrossRef

39.

Dauvilliers Y, Carlander B, Rivier F (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905–908. https://doi.org/10.1002/ana.20339 CrossRef

40.

de Oliveira MM, Conti C, Prado GF (2016) Pharmacological treatment for Kleine Levin syndrome. Cochrane Database Syst Rev 25:486–496. https://doi.org/10.1002/14651858.CD006685.pub4.2016 CrossRef

41.

Leu-Semenescu S, Le Corvec T, Groos E, Lavault S, Golmard JL, Arnulf I (2015) Lithium therapy in Kleine-Levin syndrome: an open-label, controlled study in 130 patients. Neurology 85:1655–1662. https://doi.org/10.1212/WNL.0000000000002104 CrossRef

42.

Trotti LM, Saini P, Bliwise DL, Freeman AA, Jenkins A, Rye DB (2015) Clarithromycin in ɣ-aminobutyric acid-related hypersomnolence: a randomized, cross-over trial. Ann Neurol 78:454–465. https://doi.org/10.1002/ana.24459 CrossRef

43.

PDR.net (2016) Available from: https://www.fda.gov/Drugs/DrugSafety/ucm332029.htm

44.

Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP (1986) Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 9:260–264. https://doi.org/10.1093/sleep/9.1.260 CrossRef

45.

Honda Y, Hishikawa Y, Takahashi Y (1979) Long-term treatment of narcolepsy with methylphenidate (Ritalin). Curr Ther Res 25:288–298

46.

Leonard BE, McCartan D, White J, King DJ (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19:151–180. https://doi.org/10.1002/hup.579 CrossRef

47.

Mignot EJ (2012) A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 9:739–752. https://doi.org/10.1007/s13311-012-0150-9 CrossRef

48.

Mayer G, Meier-Ewert K, Hephata K (1995) Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18:306–319CrossRef

49.

Larrosa O, de la Llave Y, Barrio S, Granizo JJ, Garcia-Borreguero D (2001) Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 24:282–285. https://doi.org/10.1093/sleep/24.3.282 CrossRef

50.

Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, Inoue Y, Honda M (2013) Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One 8:e53707. https://doi.org/10.1371/journal.pone.0053707 CrossRef

51.

Barateau L, Lopez R, Dauvilliers Y (2016) Management of narcolepsy. Curr Treat Opin Neurol 18:43. https://doi.org/10.1007/s11940-016-0429-y CrossRef

52.

Shindler J, Schachter M, Brincat S, Parkes JD (1985) Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 290:1167–1170CrossRef

53.

Alvarez B, Dahlitz M, Grimshaw J, Parkes JD (1991) Mazindol in long-term treatment of narcolepsy. Lancet Lond Engl 337:1293–1294CrossRef

54.

Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y (2019) A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol 85:359–370. https://doi.org/10.1002/ana.25423 CrossRef

55.

Sleepfoundation.org (2019) Sleep apnea | National Sleep Foundation. [online] Available: https://www.sleepfoundation.org/sleep-disorders-problems/sleep-apnea

56.

Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y (2012) Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 16:431–443. https://doi.org/10.1016/j.smrv.2011.09.001 CrossRef

57.

Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS (2012) Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 8:451–458. https://doi.org/10.5664/jcsm.2048 CrossRef

58.

Scrima L, Hartman PG, Johnson FH Jr, Hiller FC (1989) Efficacy of gammahydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 26:331–343CrossRef

59.

Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J (1993) Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 16:216–220. https://doi.org/10.1093/sleep/16.3.216 CrossRef

60.

US Xyrem Multicenter Study Group (2002) A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25:42–49. https://doi.org/10.1093/sleep/25.1.42 CrossRef

61.

US Xyrem Multicenter Study Group (2003) A 12-month, open- label multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 26:31–35. https://doi.org/10.1093/sleep/26.1.31 CrossRef

62.

Mayer G, Plazzi G, Iranzo Á, Ortega-Albás J, Quinnell T, Pesch H, Serralheiro P, Schlit AF, Wuiame D, Bentz JWG (2018) Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep 41(9). https://doi.org/10.1093/sleep/zsy128

63.

Pillen S, Pizza F, Dhondt K, Scammell TE, Overeem S (2017) Cataplexy and its mimics: clinical recognition and management. Curr Treat Options Neurol 19:23. https://doi.org/10.1007/s11940-017-0459-0 CrossRef

64.

Wang J, Greenberg H (2013) Status cataplecticus precipitated by abrupt withdrawal of venlafaxine. J Clin Sleep Med 15:715–716. https://doi.org/10.5664/jcsm.2848 CrossRef

65.

Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M (2017) The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the committee for medicinal products for human use. Sleep Med 33:125–129. https://doi.org/10.1016/j.sleep.2017.01.002 CrossRef

66.

Szakacs Z, Dauvilliers Y, Mikhaylov V et al (2017) HARMONY-CTP study group. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200–207. https://doi.org/10.1016/S1474-4422(16)30333-7 CrossRef

67.

Langdon N, Bandak S, Shindler J, Bandak S (1986) Fluoxetine in the treatment of cataplexy. Sleep 9:371–372. https://doi.org/10.1093/sleep/9.2.371 CrossRef

68.

Frey J, Darbonne C (1994) Fluoxetine suppresses human cataplexy: a pilot study. Neurology 44:707–709CrossRef

69.

Thirumalai SS, Shubin RA (2000) The use of citalopram in resistant cataplexy. Sleep Med 1:313–316. https://doi.org/10.1016/S1389-9457(00)00026-5 CrossRef

70.

Poryazova R, Siccoli M, Werth E, Basssetti CL (2005) Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 65:967–968. https://doi.org/10.1212/01.wnl.0000175978.61048.62 CrossRef

71.

Schachter M, Parkes JD (1980) Fluvoxamine and clomipramine in the treatment of cataplexy. JNNP 43:171–174

72.

Shapiro WR (1975) Treatment of cataplexy with clomipramine. Arch Neurol 32:653–656. https://doi.org/10.1001/archneur.1975.00490520023002 CrossRef

73.

Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W (1976) Evaluation of shortterm and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 54:71–87. https://doi.org/10.1111/j.1600-0404.1976.tb07621.x CrossRef

74.

Rugino T (2007) A review of modafinil film-coated tablets for attention deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat 3:293–301

75.

Ivanenko A, Tauman R, Gozal D (2003) Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 4:579–582. https://doi.org/10.1007/s13311-012-0149-2 CrossRef

76.

Inocente CO, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimão R, Lin JS, Franco P (2012) Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. ClinNeuropharmacol 35:55–60. https://doi.org/10.1097/WNF.0b013e318246879d CrossRef

77.

Moresco M, Pizza F, Antelmi E, Plazzi G (2018) Sodium oxybate treatment in pediatric type 1 narcolepsy. Curr Drug Metab 19:1073–1079. https://doi.org/10.2174/1389200219666180305153134 CrossRef

78.

Murali H, Kotagal S (2006) Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 29:1025–1029. https://doi.org/10.1093/sleep/29.8.1025 CrossRef

79.

Plazzi G, Clawges HM, Owens JA (2018) Clinical characteristics and burden of illness in pediatric patients with narcolepsy. Pediatr Neurol 85:21–32. https://doi.org/10.1016/j.pediatrneurol.2018.06.008 CrossRef

80.

FDA approves new treatment of cataplexy and excessive daytime sleepiness in pediatric patients with narcolepsy- drug information update [news release] (2018) Silver Spring, MD: FDA Division of Drug Information

81.

Nishino S, Kotorii N (2016) Modes of action of drugs related to narcolepsy:pharmacology of wake-promoting compounds and anticataplectics. In: Goswami M, Thorpy MJ, Pandi-Perumal SR (eds) Narcolepsy. A clinical guide. Springer International Publishing, Switzerland, pp 307–329CrossRef

82.

Dopheide JA, Pilszka SR (2009) Attention-deficit disorder: an update. Pharmacotherapy 29:656–679CrossRef

83.

Product information (2007) Dextroamphetamine sulfate oral tablets, dextroamphetamine sulfate oral tablets. St. Louis: Mallinckrodt; 2007

84.

Product information (2007) RITALIN: oral tablets, methylphenidate hydrochloride oral tablets. East Hanover, NJ: Novartis; 2007

85.

Kotagal S (2018) Treatment of narcolepsy and other organic hypersomnias in children. Paediatr Respir Rev 25:19–24. https://doi.org/10.1016/j.prrv.2017.06.012 CrossRef

86.

Ristanovic RK, Llang H, Hornfeldt CS, Lai C (2009) Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy. Sleep Med 10:416–421. https://doi.org/10.1016/j.sleep.2008.04.004 CrossRef

87.

Lopez R, Dauvilliers Y (2013) Pharmacotherapy options for cataplexy. Expert Opin Pharmacother 14:895–903. https://doi.org/10.1517/14656566.2013.783021 CrossRef

88.

Ratkiewicz M, Splaingard M (2013) Treatment of cataplexy in a three-year-old using venlafaxine. J Clin Sleep Med 15:1341–1342. https://doi.org/10.5664/jcsm.3284 CrossRef

89.

Moller L, Ostergaard J (2009) Treatment with venlafaxine in six cases of children with narcolepsy with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol 19:197–201. https://doi.org/10.1089/cap.2008.036 CrossRef

90.

Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, Mignot E, Cicognani A, Montagna P (2008) Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 255:1549–1554. https://doi.org/10.1007/s00415-008-0983-7 CrossRef

91.

Knudsen S, Biering-Sørensen B, Kornum BR, Petersen ER, Ibsen JD, Gammeltoft S, Mignot E, Jennum PJ (2012) Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology 3:102–103. https://doi.org/10.1212/WNL.0b013e31825dce03 CrossRef

92.

Lecendreux M, Berthier J, Corny J, Bourdon O, Dossier C, Delclaux C (2017) Intravenous immunoglobulin therapy in pediatric narcolepsy: a nonrandomized, open-label, controlled, longitudinal observational study. J Clin Sleep Med 15:441–453. https://doi.org/10.5664/jcsm.6500 CrossRef

93.

Ruppert E, Zagala H, Chambe J, Comtet H, Kilic-Huck U, Lefebvre F, Bataillard M, Schroder C, Calvel L, Bourgin P (2018) Intravenous immunoglobulin therapy administered early after narcolepsy type 1 onset in three patients evaluated by clinical and polysomnographic follow-up. BehavNeurol15;2018:1671072. https://doi.org/10.1155/2018/1671072

94.

Pizza F, Franceschini C, Peltola H (2013) Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 136:3787–3795. https://doi.org/10.1093/brain/awt277 CrossRef

95.

Donjacour C, Mets MAJ, Verster JC (2010) Narcolepsy, driving and traffic safety. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 217–222CrossRef

96.

Lindsley G (2010) Narcolepsy, intimacy and sexuality. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 205–216CrossRef

97.

Naumann A, Bellebaum C, Daum I (2006) Cognitive deficits in narcolepsy. J Sleep Res 15:329–338. https://doi.org/10.1111/j.1365-2869.2006.00533.x CrossRef

98.

Bellebaum C, Daum I (2010) Memory and cognition in narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 223–230CrossRef

99.

Vignatelli L, Plazzi G, Peschechera F, Delaj L, D’Alessandro R (2011) A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Med 12:19–23. https://doi.org/10.1016/j.sleep.2010.07.008 CrossRef

100.

Ingravallo F, Plazzi G (2010) Medico-legal aspects of disability in narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 231–238CrossRef

101.

Shneerson J (2010) Narcolepsy and mental health. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 239–250CrossRef

102.

Britton T, Hansen A, Hicks J, Howard R, Meredith A (2002) Guidelines on the diagnosis and management of narcolepsy in adults and children. Evidence-based guidelines for the UK with graded recommendations. Taylor Patten Communications Ltd, Ashtead

103.

Billiard M, QueraSalva M, de Koninck J, Besset A, Touchon J, Cahilhac J (1986) Daytime sleep characteristics and night sleep in the narcoleptic patient. Sleep 9:167–174. https://doi.org/10.1093/sleep/9.1.167 CrossRef

104.

Overeem S, Reading P, Bassetti CL (2012) Narcolepsy. Sleep Med Clin 7:263–281CrossRef

105.

Krahn LE, Hershner S, Loeding LD, Maski KP, Rifkin DI, Selim B, Watson NF (2015) Quality measures for the care of patients with narcolepsy. J Clin Sleep Med 11:335. https://doi.org/10.5664/jcsm.4554 CrossRef

106.

Mullington J, Broughton R (1993) Scheduled naps in the management of daytime sleepiness in narcolepsy cataplexy. Sleep 16:444–456. https://doi.org/10.1093/sleep/16.5.444 CrossRef

107.

Yuchiyama MG, Mayer G, Meier-Ewert K (1994) Differential effects of extended sleep in narcoleptics patients. Electroencephalogr Clin Neurophysiol 91:212–218CrossRef

108.

Bhattarai J, Sumerall S (2017) Current and future treatment options for narcolepsy: a review. Sleep Sci 10:19–27. https://doi.org/10.5935/1984-0063.20170004 CrossRef

109.

Rogers AE (1984) Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nurs 16:326–334CrossRef

110.

Bruck D, Broughton R (2001) Achieving control over sleepiness in narcolepsy. Aust J Prim Health 7:16–24CrossRef

111.

Marin-Agudelo H (2011) Multicomponent cognitive behavioral treatment efficacy for narcolepsy (MCBT-N). Sleep Med 12:S55–S42. https://doi.org/10.1016/j.slsci.2014.07.023 CrossRef

112.

Conroy DA, Novick DM, Swanson LM (2012) Behavioral management of hypersomnia. Sleep Med Clin 7:325–331CrossRef

113.

Marín-Agudelo H, Jiménez Correa U (2012) Scheduled naps and systematic desensitization in the emotional processing in patients with narcolepsy: a comparative study of autonomic and cognitive evoked potentials. Sleep 35:A275

114.

Marín-Agudelo H, Jiménez Correa U (2013) Beliefs and dysfunctional attitudes in patients with narcolepsy; double-blind study of treatment efficacy. Sleep 36(Suppl: A256)

115.

Espana RA, McCormack SL, Mochizuki T, Scammell TE (2007) Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 30:1417–1425. https://doi.org/10.1093/sleep/30.11.1417 CrossRef

116.

Filardi M, Pizza F, Antelmi E, Pillastrini P, Natale V, Plazzi G (2018) Physical activity and sleep/wake behavior, anthropometric, and metabolic profile in pediatric narcolepsy type 1. Front Neurol 9:707. https://doi.org/10.3389/fneur.2018.00707 CrossRef

117.

MarínAgudelo HA, Jiménez Correa U, Carlos Sierra J, Pandi-Perumal SR, Schenck CH (2014) Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy? Sleep Sci 7:30–42. https://doi.org/10.1016/j.slsci.2014.07.023 CrossRef

118.

Dennis CL (2003) Peer support within a health care context: a concept analysis. Int J Nurs Stud 40:321–332. https://doi.org/10.1016/S0020-7489(02)00092-5 CrossRef

119.

Embuldeniya G, Veinot P, Bell E, Nyhof-Young J, Sale JE, Britten N (2013) The experience and impact of chronic disease peer support interventions: a qualitative synthesis. Patient Educ Couns 92:3–12. https://doi.org/10.1016/j.pec.2013.02.002 CrossRef

120.

Shilling V, Morris C, Thompson-Coon J, Ukoumunne O, Rogers M, Logan S (2013) Peer support for parents of children with chronic disabling conditions: a systematic review of quantitative and qualitative studies. Dev Med Child Neurol 55:602–609. https://doi.org/10.1111/dmcn.12091 CrossRef

121.

Anderson M, Elliott EJ, Zurynski YA (2013) Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis 8:1–9. https://doi.org/10.1186/1750-1172-8-22 CrossRef

122.

Kippola-Pääkkönen A, Härkäpää K, Valkonen J, Tuulio-Henriksson A, Autti-Rämö I (2016) Psychosocial intervention for children with narcolepsy: parents’ expectations and perceived support. J Child Health Care 20:521–529. https://doi.org/10.1177/1367493516643420 CrossRef

123.

Dauvilliers Y, Roth T, Giunta D et al (2017) Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med 40:53–57. https://doi.org/10.1016/j.sleep.2017.07.030 CrossRef

124.

Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, Zee P (2013) Disrupted nighttime sleep in narcolepsy. J Clin Sleep 9:955–965. https://doi.org/10.5664/jcsm.3004 CrossRef

125.

European Commission (2014) Implementation report on the commission communication on rare diseases: Europe’s challenges and council recommendation of 8 June 2009 on an action in the field of rare diseases. Available at: http://ec.europa.eu/health/rare_diseases/docs/2014_rarediseases_implementationreport_en.pdf

Titel: Narcolepsy treatment: pharmacological and behavioral strategies in adults and children
verfasst von: Christian Franceschini
Fabio Pizza
Elena Antelmi
Maria Claudia Folli
Giuseppe Plazzi
Publikationsdatum: 10.07.2019
Verlag: Springer International Publishing
Erschienen in: Sleep and Breathing / Ausgabe 2/2020
Print ISSN: 1520-9512
Elektronische ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-019-01894-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

The association of OSAS and uvula: the role of MRI in this egg-chicken problem in OSAS

Excessive daytime sleepiness in narcolepsy and central nervous system hypersomnias

Effect-size seed-based d mapping of resting-state fMRI for persistent insomnia disorder

The efficacy of mind-body (Baduanjin) exercise on self-reported sleep quality and quality of life in elderly subjects with sleep disturbances: a randomized controlled trial

Prevalence of poor sleep quality in the Ethiopian population: a systematic review and meta-analysis

Evaluation of an OSA risk stratifying and treatment protocol during inpatient rehabilitation of post-stroke patients